CZChen Zhang

Chen Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chen Zhang has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Short-Term Relief with Upadacitinib: A Case Report of Palmoplantar Pustulosis in a Pediatric Patient

    by Qinchen Gu, Chen Zhang, Zhimin Lin, Yiting Fu, Chen Li, Zhenhua Ying

    Palmoplantar pustulosis (PPP) is a chronic inflammatory skin disease with recurrent erythema, scales, and sterile pustules on the palms and soles. Treating PPP in children is difficult due to limited effective therapies, especially as there’s a lack of data on upadacitinib use in children under 12.This article reports a pediatric PPP case. The patient had severe, recurring rashes that affected daily activities. Treated with upadacitinib for two months, she showed a significant therapeutic response.


  • Red cell distribution width/albumin ratio and mortality risk in rheumatoid arthritis patients: Insights from a NHANES study

    by Chen Zhang, Siyi Lu, Tianlun Kang, Fanzhang Meng, Tangliang Qian, Xiaoping Liu, Zhi Liu, Xiujuan Hou

    Background: Despite the established negative regulatory effects observed in various diseases like cardiovascular disease and diabetes, the distinct impact of red cell distribution width (RDW) to albumin ratio (RAR) on mortality within the realm of rheumatoid arthritis (RA) remains obscure. This study sought to explore the relationship between RAR and mortality in RA patients.Methods: A cohort of 2151 adults with RA from the National Health and Nutrition Examination Survey (NHANES) spanning 2003–2016 was analyzed for RAR levels derived from red cell distribution width and albumin concentrations. Utilizing Cox regression analysis, Kaplan–Meier curves, and Restricted Cubic Spline (RCS) models, we assessed the association between RAR levels and RA mortality while adjusting for potential confounding variables.Results: Participants with higher RAR had a twofold to threefold increased risk of all‐cause (HR = 3.10, 95% CI: 2.26–4.24) and cardiovascular mortality (HR = 2.46, 95%CI: 1.26–4.79) versus lower RAR. Kaplan–Meier analysis revealed that the higher RAR group had a significantly lower survival rate compared to the lower RAR group for both all‐cause and cardiovascular mortality (both p < .0001), with a more pronounced effect observed for all‐cause mortality. Furthermore, the RCS‐fitted Cox regression model illustrated a nonlinear positive correlation between RAR levels and RA mortality.Conclusion: Overall, a higher RAR was associated with an increased risk mortality in RA patients. These findings underscore the potential of RAR as a prognostic biomarker in predicting outcomes in RA.


  • Association between oxidative balance score and risk of gout: The NHANES cross‐sectional study, 2007–2018

    by Fanzhang Meng, Siyi Lu, Yingzi Li, Chen Zhang, Tianlun Kang, Tangliang Qian, Chao Tan, Xiaoping Liu, Xiujuan Hou

    Background: The Oxidative Balance Score (OBS) is a systematic tool to assess the effects of diet and lifestyle in relation to oxidative stress. The association between OBS and gout has not been reported previously. We conducted a cross‐sectional study to investigate the complex association between OBS and gout in US adults.Methods: In all, 10 492 participants were included in this study. The exposure variable was OBS, which was scored by 16 dietary and four lifestyle factors. Multivariate logistic regression, subgroup analysis, and restricted cubic spline (RCS) regression were used to analyze the association between OBS and gout.Results: Compared with the lowest OBS quartile group (Q1), the multivariate corrected odds ratio (OR) (95% confidence interval [C]) for the highest quartile of OBS (Q4) was 0.72 (0.52–1.00) (p = .13 for trend); furthermore, the RCS showed a negative linear relationship between OBS and gout (p‐nonlinear = .606).Conclusion: In conclusion, the risk of gout is higher with high OBS. The prevalence of gout decreased with higher OBS. Diabetes may alter this negative correlation.


  • Open Access

    Pregnancy outcomes following tofacitinib use for SAPHO syndrome: a case report

    by Chen Zhang, Xiaojun Shi, Tangliang Qian, Xiaoping Liu, Yihang Ding, Xiujuan Hou, Chen Li

    Tofacitinib, an oral Janus kinase inhibitor, has demonstrated teratogenic effects in animal models. However, there is a lack of data on its effects during human pregnancy, especially in the context of synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome, a rare disease. We report a case of a 31-year-old female patient with SAPHO syndrome who became pregnant unexpectedly after 5 weeks of continuous tofacitinib treatment during the first trimester. Tofacitinib was immediately discontinued upon discovering the pregnancy. The patient successfully delivered a healthy full-term male infant under vigilant monitoring, and her SAPHO syndrome symptoms ameliorated during gestation but exacerbated 40 days postpartum. Given the limited clinical data available, further monitoring of pregnancy outcomes in patients treated with tofacitinib is still warranted.

  • Open Access

    Secukinumab-Induced Alopecia Areata Successfully Treated with Tofacitinib in a Patient with Palmoplantar Pustulosis

    by Chen Zhang, Tianlun Kang, Tangliang Qian, Mingwei Ma, Xiujuan Hou, Chen Li

    Secukinumab, a monoclonal antibody targeting interleukin-17 (IL-17), has exhibited encouraging results in the therapeutic management of palmoplantar pustulosis (PPP). The development of alopecia areata (AA) is closely related to IL-17, and IL-17A inhibitors were considered as a potential treatment modality. Therefore, the development of AA during secukinumab treatment for PPP is a rare adverse event that has been rarely reported worldwide. Here we report a 35-year-old female patient with PPP who developed AA after completing the induction period of secukinumab treatment. Discontinuing secukinumab and initiating treatment with tofacitinib resulted in a significant improvement in both PPP and AA. The emergence of AA in this patient can be attributed to paradoxical skin reactions associated with IL-17 inhibitors. Tofacitinib appears to alleviate biologic-induced AA during PPP syndrome treatment.